{"id":"87f06efd2271","type":"article","url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","title":"Antihypertensieve regimes in SPRINT gedetailleerd beschreven","title_en":"Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lorundrostat"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.122.20373","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.122.20373","authors":["Catherine G Derington","Adam P Bress","Andrew E Moran","William S Weintraub","Jennifer S Herrick","William C Cushman","Ian M Kronish","Barry Stults","Daichi Shimbo","Paul Muntner","Tom Greene","Jeffrey T Bates","Tara I Chang","Lois Anne Katz","Shakaib U Rehman","Christianne L Roumie","Leonardo Tamariz","Jordan B King"],"significance":6,"published":"2023-03-01","source_date":"2023-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/thiazidediuretica-hypertensie/","https://hartvaat.nl/kennis/hypertensie/centrale-middelen-hypertensie/"],"congress":"","summary_en":"This detailed description of antihypertensive regimens used in SPRINT showed that the intensive group required more RAAS inhibitors and diuretics, contextualizing the treatment strategy behind the landmark trial's results.","created":"2026-07-03T10:30:15Z","updated":"2026-07-03T18:39:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gedetailleerde beschrijving van de antihypertensieve medicatieregimes in SPRINT. De intensieve groep gebruikte vaker RAAS-remmers, thiaziden en calciumantagonisten. Het aantal middelen en de keuze varieerden sterk, wat praktische handvatten biedt voor implementatie.","abstract_original":"BACKGROUND: Describing the antihypertensive medication regimens used in the SPRINT (Systolic Blood Pressure Intervention Trial) would contextualize the standard and intensive systolic blood pressure (SBP) interventions and may inform future implementation efforts to achieve population-wide intensive SBP goals. METHODS: We included SPRINT participants with complete medication data at the prerandomization and 12-month visits. Regimens were categorized by antihypertensive medication class. Analyses were stratified by treatment group (standard goal SBP <140 mm Hg versus intensive goal SBP <120 mm Hg). RESULTS: Among 7860 participants (83.7% of 9361 randomized), the median number of classes used at the prerandomization visit was 2.0 and 2.0 in the standard and intensive groups (P=0.559). At 12-months, the median number of classes used was 3.0 and 2.0 in the intensive and standard groups (P<0.001). Prerandomization, angiotensin-converting enzyme inhibitor (ACE), or angiotensin-II receptor blocker (ARB) monotherapy was the most common regimen in the intensive and standard groups (12.6% versus 12.2%). At 12-months, ACE/ARB monotherapy was still the most common regimen among standard group participants (14.7%) and was used by 5.3% of intensive group participants. Multidrug regimens used by the intensive and standard participants at 12 months were as follows: an ACE/ARB with thiazide (12.2% and 7.9%); an ACE/ARB with calcium channel blocker (6.2% and 6.8%); an ACE/ARB, thiazide, and calcium channel blocker (11.4% and 4.3%); and an ACE/ARB, thiazide, calcium channel blocker, and beta-blocker (6.5% and 1.2%). CONCLUSIONS: SPRINT investigators favored combining ACEs or ARBs, thiazide diuretics, and calcium channel blockers to target SBP <120 mm Hg, compared to ACE/ARB monotherapy to target SBP <140 mm Hg. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT01206062."}